Toth Financial Advisory’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Toth Financial Advisory’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-200	Closed	-$1K	–	847
2021 Q3	$1K	Hold	200	–	–	﹤0.01%	745
2021 Q2	$1K	Hold	200	–	–	﹤0.01%	688
2021 Q1	$2K	Hold	200	–	–	﹤0.01%	625
2020 Q4	$2K	Hold	200	–	–	﹤0.01%	564
2020 Q3	$2K	Buy	200 +50	+33%	+$346	﹤0.01%	509
2020 Q2	$1K	Hold	150	–	–	﹤0.01%	539
2020 Q1	$1K	Hold	150	–	–	﹤0.01%	449
2019 Q4	$1K	Hold	150	–	–	﹤0.01%	476
2019 Q3	$1K	Buy	+150	New	+$1.3K	﹤0.01%	463

Other funds holding KLDO

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Toth Financial Advisory's KLDO Position: Q4 2021 in Review

Toth Financial Advisory sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q4 2021, closing a stake of 200 shares — an estimated $1K sold.

Toth Financial Advisory first reported a position in KLDO in Q3 2019 and held it in 9 quarters. The position peaked at $2K in Q1 2021. 66 funds tracked by Wall St. Rank hold KLDO as of Q4 2021.

Toth Financial Advisory reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Toth Financial Advisory sold 200 Kaleido Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $1K.
Toth Financial Advisory first reported a position in Kaleido Biosciences, Inc. Common Stock in Q3 2019 and held it in 9 quarters.
Toth Financial Advisory's Kaleido Biosciences, Inc. Common Stock position peaked at $2K in Q1 2021.
66 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q4 2021.

Based on Toth Financial Advisory's 13F filing for Q4 2021, filed 31 Jan 2022.